HRP980521A2 - THE USE OF Na+/H+ EXCHANGER INHIBITOR IN THE PRODUCTION OF A MEDICAMENT FOR TREATMENT OR PROPHYLAXIS OF DISEASES OF THE CENTRAL NERVOUS SYSTEM - Google Patents

THE USE OF Na+/H+ EXCHANGER INHIBITOR IN THE PRODUCTION OF A MEDICAMENT FOR TREATMENT OR PROPHYLAXIS OF DISEASES OF THE CENTRAL NERVOUS SYSTEM

Info

Publication number
HRP980521A2
HRP980521A2 HR19750498.1A HRP980521A HRP980521A2 HR P980521 A2 HRP980521 A2 HR P980521A2 HR P980521 A HRP980521 A HR P980521A HR P980521 A2 HRP980521 A2 HR P980521A2
Authority
HR
Croatia
Prior art keywords
alkyl
substituted
group
atoms
zero
Prior art date
Application number
HR19750498.1A
Other languages
English (en)
Croatian (hr)
Inventor
Martin Wiemann
Original Assignee
Hoechst Marion Roussel De Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19742096A external-priority patent/DE19742096A1/de
Priority claimed from DE1997150498 external-priority patent/DE19750498A1/de
Application filed by Hoechst Marion Roussel De Gmbh filed Critical Hoechst Marion Roussel De Gmbh
Publication of HRP980521A2 publication Critical patent/HRP980521A2/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HR19750498.1A 1997-09-24 1998-09-23 THE USE OF Na+/H+ EXCHANGER INHIBITOR IN THE PRODUCTION OF A MEDICAMENT FOR TREATMENT OR PROPHYLAXIS OF DISEASES OF THE CENTRAL NERVOUS SYSTEM HRP980521A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19742096A DE19742096A1 (de) 1997-09-24 1997-09-24 Die Verwendung eines Inhibitors des Na·+·/H·+·-Austauschers zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von Erkrankungen des Zentralnervensystems
DE1997150498 DE19750498A1 (de) 1997-11-14 1997-11-14 Die Verwendung eines Inhibitors des Na+/H+-Austauschers zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von Erkrankungen des Zentralnervensystems

Publications (1)

Publication Number Publication Date
HRP980521A2 true HRP980521A2 (en) 1999-06-30

Family

ID=26040251

Family Applications (1)

Application Number Title Priority Date Filing Date
HR19750498.1A HRP980521A2 (en) 1997-09-24 1998-09-23 THE USE OF Na+/H+ EXCHANGER INHIBITOR IN THE PRODUCTION OF A MEDICAMENT FOR TREATMENT OR PROPHYLAXIS OF DISEASES OF THE CENTRAL NERVOUS SYSTEM

Country Status (17)

Country Link
US (1) US20040097544A1 (pt)
EP (1) EP0909559A2 (pt)
JP (1) JPH11158082A (pt)
KR (1) KR19990030008A (pt)
CN (1) CN1212149A (pt)
AR (1) AR015724A1 (pt)
AU (1) AU750355B2 (pt)
BR (1) BR9803597A (pt)
CA (1) CA2247733A1 (pt)
CZ (1) CZ304698A3 (pt)
HR (1) HRP980521A2 (pt)
HU (1) HUP9802142A2 (pt)
IL (1) IL126276A0 (pt)
NO (1) NO984430L (pt)
NZ (1) NZ332004A (pt)
SK (1) SK130398A3 (pt)
TR (1) TR199801887A2 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2617709B8 (en) * 2003-06-26 2022-12-21 Biotron Limited Guanidine derivatives as antiviral agents
CN102870764A (zh) * 2011-07-13 2013-01-16 刘斌 一种新型灌注保存液

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3929582A1 (de) * 1989-09-06 1991-03-07 Hoechst Ag Benzoylguanidine, verfahren zu ihrer herstellung, ihre verwendung als medikament sowie sie enthaltendes medikament
ES2097409T3 (es) * 1992-09-22 1997-04-01 Hoechst Ag Benzoilguanidinas, procedimiento para su preparacion, asi como su empleo como antiarritmicos.
DE4318756A1 (de) * 1993-06-05 1994-12-08 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE4325822A1 (de) * 1993-07-31 1995-02-02 Hoechst Ag Substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
DE19531138A1 (de) * 1995-08-24 1997-02-27 Merck Patent Gmbh Alkenyl-benzoylguanidin-Derivate
US5811244A (en) * 1996-09-18 1998-09-22 The Jackson Laboratory In vitro method for identifying a clinical disorder associated with Nhe1 mutation

Also Published As

Publication number Publication date
IL126276A0 (en) 1999-05-09
KR19990030008A (ko) 1999-04-26
AU8615798A (en) 1999-04-15
HU9802142D0 (en) 1998-11-30
TR199801887A2 (xx) 1999-04-21
US20040097544A1 (en) 2004-05-20
EP0909559A2 (de) 1999-04-21
AR015724A1 (es) 2001-05-16
AU750355B2 (en) 2002-07-18
NZ332004A (en) 2001-04-27
CA2247733A1 (en) 1999-03-24
BR9803597A (pt) 2000-03-21
NO984430L (no) 1999-03-25
CZ304698A3 (cs) 1999-04-14
SK130398A3 (en) 1999-05-07
NO984430D0 (no) 1998-09-23
CN1212149A (zh) 1999-03-31
HUP9802142A2 (hu) 1999-04-28
JPH11158082A (ja) 1999-06-15

Similar Documents

Publication Publication Date Title
US5614560A (en) Method of preventing NMDA receptor-mediated neuronal damage
CA2257299A1 (en) Use of inhibitors of the cellular na+/h+ exchanger (nhe) for production of a medicament for the normalization of serum lipids
JPH05509077A (ja) N,n’―二置換グアニジン類及びそれらの興奮性アミノ酸アンタゴニストとしての用途
HRP980464A2 (en) Combined pharmaceutical preparation containing a sodium-hydrogen exchanger inhibitor and a medicament for heart circulation diseases treatment
CA2117592A1 (en) N,n'-disubstituted guanidines and their use as excitatory amino acid antagonists
JP2006077034A (ja) Nmda受容体媒介性神経障害の防止薬剤
KR970707139A (ko) 평활근 세포 증식의 억제제로서의 다음이온성 벤질글리코사이드(Polyanionic benzylglycosides as inhibitors of smooth muscle cell proliferation)
AU717247B2 (en) Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for the production of a medicament for respiratory stimulation
RU2010139571A (ru) Производные 4-(2-амино-1-гидроксиэтил)фенола в качестве агонистов b2-адренергического рецептора
HRP980521A2 (en) THE USE OF Na+/H+ EXCHANGER INHIBITOR IN THE PRODUCTION OF A MEDICAMENT FOR TREATMENT OR PROPHYLAXIS OF DISEASES OF THE CENTRAL NERVOUS SYSTEM
US6420430B1 (en) Use of inhibitors of the sodium-hydrogen exchanger for preparing a medicament for preventing age-related disorders, and for prolonging life
HRP980468A2 (en) Use of inhibitors of the sodium hydrogen exchange in the manufacture of a medicament for treating diseases cused by protozoa
HRP980488A2 (en) The use of a sodium-hydrogen exchanger inhibitor in the production of a medicine for the prevention of undesirable effects of substances to a heart
DE19750498A1 (de) Die Verwendung eines Inhibitors des Na+/H+-Austauschers zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von Erkrankungen des Zentralnervensystems
DE19742096A1 (de) Die Verwendung eines Inhibitors des Na·+·/H·+·-Austauschers zur Herstellung eines Medikaments zur Behandlung oder Prophylaxe von Erkrankungen des Zentralnervensystems
MXPA98006923A (en) Pharmaceutical combined preparation based on an inhibitor of the exchanger between sodium and hydrogen and of a medicine intended for the treatment of cardio-circulatory diseases
JP2002012543A (ja) N,n’−ジ置換グアニジンおよび興奮性アミノ酸アンタゴニストとしてのそれらの用途

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
PNAN Change of the applicant name, address/residence

Owner name: AVENTIS PHARMA DEUTSCHLAND GMBH, DE

ODBI Application refused